Eli Lilly (NYSE: LLY) has achieved a major milestone by securing regulatory approval for its weight management drug, Mounjaro, in China. This development, confirmed through the company’s ...

Suzhou-based Innovent Biologics secured approval last week for its treatment mazdutide. Read more at straitstimes.com. Read ...

In a breakthrough for incretin medicines, China’s National Medical Products Administration (NMPA) has approved Innovent’s ...

You've heard about the likes of Ozempic, Wegovy and Mounjaro, jabs which a growing number of people are taking in an attempt ...

A fast-growing group of Americans are turning to what many call the "gray market" for obesity medicines, bringing cheap ...

Suzhou-based Innovent Biologics secured approval last week for its treatment mazdutide, a turning point in China’s efforts ... local alternative to Novo and Lilly’s blockbuster GLP-1 treatments could ...

Eli Lilly, the global pharmaceutical giant, said the Therapeutic Goods Administration had approved the use of its Mounjaro weight-loss drug to treat moderate-to-severe obstructive sleep apnoea in ...

Mean body weight reductions after 24 weeks ranged from 8.2% to 10.3% in the MDR-001 cohorts, versus 2.5% in the placebo arm.

TUESDAY, June 24, 2025 (HealthDay News) — A new Chinese-developed GLP-1 weight loss drug could prove a new competitor to ...

This summary covers recent developments in health from the death tied to a cyberattack on Synnovis services in the UK, the Eli Lilly and Novo Nordisk rivalry in the weight-loss drug market in India, ...

In what she calls the "wild west" of obesity medicines, Missouri-based Amy Spencer is a pioneer.

The 85th American Diabetes Association Scientific Sessions have shown the depth of China’s play for the GLP-1 market, with Corxel Pharmaceuticals and Sciwind Biosciences among the companies to share ...